EGFR and endometriosis: A previous study suggested that tetrahydropalmatine, an active substance in YHS, exerts a therapeutic effect on dysmenorrhea caused by endometriosis by intervening in the EGFR/PI3K/AKT signaling pathway (Zhang et al., 2025).